This patent protects important intermediates in Alchemia’s synthetic process and provides Alchemia with the legal means to prevent other companies from using these intermediates, or selling product derived from these intermediates, in the US.
A notice of allowance is a notification to the patent applicant that they are entitled to a patent under the law and is issued for applications that have been filed based on intent to use. The patent number will be assigned on payment of the grant fees.
Pete Smith, CEO of Alchemia, said: “The allowance of this patent provides significant protection for Alchemia’s improved synthetic process and a further barrier to entry for other generic manufacturers. Our preparations for filing for approval are advancing well and today’s announcement strengthens our belief that our product will be the first and, potentially, only generic version of Arixtra.”